Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?

Alexander Ng; Pramit Khetrapal; Veeru Kasivisvanathan

doi:10.1016/j.eururo.2022.02.021

Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?

Eur Urol. 2022 Jul;82(1):1-2. doi: 10.1016/j.eururo.2022.02.021. Epub 2022 Mar 8.

Authors

Alexander Ng¹, Pramit Khetrapal², Veeru Kasivisvanathan³

Affiliations

¹ UCL Medical School, University College London, London, UK; BURST Research Collaborative, London, UK.
² Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, Whipps Cross Hospital, Barts Health NHS Trust, London, UK.
³ BURST Research Collaborative, London, UK; Division of Surgery and Interventional Science, University College London, London, UK. Electronic address: veeru.kasi@ucl.ac.uk.

PMID: 35277288
DOI: 10.1016/j.eururo.2022.02.021

Abstract

The PRIME (PRostate Imaging using Mri +/- contrast Enhancement) study is evaluating whether quicker, cheaper, and less invasive biparametric magnetic resonance imaging (bpMRI) is noninferior to multiparametric MRI in diagnosing clinically significant prostate cancer (PCa). If the study results confirm that bpMRI is not inferior, it could become the new standard of care for PCa diagnosis and streamline the diagnosis pathway so that all men who need MRI have access to this diagnostic tool.

Trial registration: ClinicalTrials.gov NCT04571840.

Keywords: Biparametric; Contrast; Diagnosis; MRI; Prostate biopsy; Prostate cancer; Screening.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Magnetic Resonance Imaging / methods
Male
Multiparametric Magnetic Resonance Imaging*
Pelvis / pathology
Prostate / pathology
Prostatic Neoplasms* / pathology

Associated data

ClinicalTrials.gov/NCT04571840

Abstract

Publication types

MeSH terms

Associated data

Grants and funding